The guidelines for clinical practice for carriers of germline mutations in the Lynch syndrome predisposition genes MLH1, MSH2, MSH6, PMS2 and large deletions of EPCAM (4.2024).
J Novotný, D Cibula, V Curtisová, O Dubová, L Foretová, A Germanová, M Janatová, O Havránek, M Hojsáková, M Hudcová, M Koudová, V Krutílková, M Palacova, S Paulich, K Petrakova, J Presl, A Puchmajerová, J Soukupová, M Šenkeříková, Z Šimková, H Štěpánková, I Šubrt, I Tachecí, P Tesner, O Urban, K Veselá, Š Vilímová, Z Vlčková, M Vočka, V Weinberger, M Zikán, M Zimovjanová, Z Kleibl, P Kleiblová
{"title":"The guidelines for clinical practice for carriers of germline mutations in the Lynch syndrome predisposition genes MLH1, MSH2, MSH6, PMS2 and large deletions of EPCAM (4.2024).","authors":"J Novotný, D Cibula, V Curtisová, O Dubová, L Foretová, A Germanová, M Janatová, O Havránek, M Hojsáková, M Hudcová, M Koudová, V Krutílková, M Palacova, S Paulich, K Petrakova, J Presl, A Puchmajerová, J Soukupová, M Šenkeříková, Z Šimková, H Štěpánková, I Šubrt, I Tachecí, P Tesner, O Urban, K Veselá, Š Vilímová, Z Vlčková, M Vočka, V Weinberger, M Zikán, M Zimovjanová, Z Kleibl, P Kleiblová","doi":"10.48095/ccko2024384","DOIUrl":null,"url":null,"abstract":"<p><p>The guidelines for clinical practice for carriers of pathogenic variants in clinically relevant genes predisposing to Lynch syndrome and colorectal cancer define the steps of primary and secondary prevention that should be provided to the individuals at high risk of developing hereditary cancer in the Czech Republic. The drafting of the guidelines was organized by the Oncogenetics Working Group of the Society for Medical Genetics and Genomics of J. E. Purkyně Czech Medical Society, in cooperation with representatives of oncology, oncogynecology, and gastroenterology. The guidelines are based on the current recommendations of the National Comprehensive Cancer Network (NCCN), European Society of Medical Oncology (ESMO) and take into account the capacity of the Czech healthcare system.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":"38 5","pages":"384-389"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinicka Onkologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.48095/ccko2024384","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
The guidelines for clinical practice for carriers of pathogenic variants in clinically relevant genes predisposing to Lynch syndrome and colorectal cancer define the steps of primary and secondary prevention that should be provided to the individuals at high risk of developing hereditary cancer in the Czech Republic. The drafting of the guidelines was organized by the Oncogenetics Working Group of the Society for Medical Genetics and Genomics of J. E. Purkyně Czech Medical Society, in cooperation with representatives of oncology, oncogynecology, and gastroenterology. The guidelines are based on the current recommendations of the National Comprehensive Cancer Network (NCCN), European Society of Medical Oncology (ESMO) and take into account the capacity of the Czech healthcare system.
针对易患林奇综合征和结直肠癌的临床相关基因致病变异携带者的临床实践指南确定了捷克共和国应向遗传性癌症高危人群提供的一级和二级预防措施。该指南由捷克医学会 J. E. Purkyně 医学遗传学和基因组学学会肿瘤遗传学工作组与肿瘤学、肿瘤妇科学和消化内科学的代表合作起草。该指南以美国国家综合癌症网络(NCCN)和欧洲肿瘤内科学会(ESMO)的现行建议为基础,并考虑了捷克医疗系统的能力。